Walleye Capital’s Crinetics Pharmaceuticals CRNX Stock Holding History

Walleye Capital’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,500	Closed	-$54.5K	–	4800
2026 Q1	$54.5K	Buy	+1,500	New	+$67K	﹤0.01%	3879
2025 Q1	–	Sell	-4,300	Closed	-$220K	–	4379
2024 Q4	$220K	Hold	4,300	–	–	﹤0.01%	3677
2024 Q3	$220K	Sell	4,300 -30,600	-88%	-$1.58M	﹤0.01%	3941
2024 Q2	$1.56M	Buy	34,900 +20,200	+137%	+$933K	﹤0.01%	2351
2024 Q1	$688K	Buy	14,700 +12,500	+568%	+$489K	﹤0.01%	2931
2023 Q4	$78.3K	Buy	+2,200	New	+$67.5K	﹤0.01%	4153

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jupiter Topco New York $245B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Walleye Capital's CRNX Position: Q2 2026 in Review

Walleye Capital sold out of Crinetics Pharmaceuticals (CRNX) in Q2 2026, closing a stake of 38,042 shares — an estimated $1.38M sold.

Walleye Capital first reported a position in CRNX in Q4 2020 and held it in 18 quarters. The position peaked at $14.1M in Q2 2024. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

Walleye Capital reported no remaining Crinetics Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Walleye Capital sold 38,042 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $1.38M.
Walleye Capital first reported a position in Crinetics Pharmaceuticals in Q4 2020 and held it in 18 quarters.
Walleye Capital's Crinetics Pharmaceuticals position peaked at $14.1M in Q2 2024.
267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.